Contribute Try STAT+ Today

In a rare move, the U.S. Food and Drug Administration has notified an untold number of drug makers that some of their clinical trials must be repeated due to serious data problems at a pair of companies in India that run studies for the pharmaceutical industry.

The action stems from inspections at two clinical research organizations — Synchron Research Services and Panexcell Clinical Lab — that were conducted in 2019. After running its own analyses, the agency found “significant instances of misconduct and violations of federal regulations, which resulted in the submission of invalid study data to FDA,” according to a Sept. 16 statement posted by the FDA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment